Discontinued — last reported Q4 '25
Eli Lilly R&D increased by 9.7% to $3.80B in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 25.8%, from $3.02B to $3.80B. Over 4 years (FY 2021 to FY 2025), R&D shows an upward trend with a 17.4% CAGR.
Analysis
StatementIncome Statement
SectionOperating Expenses
CategoryGrowth
SignalContext dependent
VolatilityStable
First reportedQ4 2014
Last reportedQ4 2025
How to read this metric
High spending signals a focus on long-term innovation, though it reduces current-period net income.
Detailed definition
Expenses related to the innovation, design, and improvement of products and services. In the technology sector, this rep...
Peer comparison
Big Tech firms often reinvest a significant percentage of revenue into R&D to maintain market leadership.
Metric ID:
is_research_and_developmentHistorical Data
19 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.67B | $1.71B | $1.96B | $1.61B | $1.78B | $1.80B | $2.00B | $1.99B | $2.36B | $2.41B | $2.56B | $2.52B | $2.71B | $2.73B | $3.02B | $2.73B | $3.34B | $3.47B | $3.80B |
| QoQ Change | — | +2.2% | +14.7% | -17.8% | +10.7% | +1.2% | +10.7% | -0.5% | +18.7% | +2.2% | +6.4% | -1.6% | +7.5% | +0.8% | +10.5% | -9.6% | +22.0% | +3.9% | +9.7% |
| YoY Change | — | — | — | — | +6.5% | +5.5% | +1.9% | +23.3% | +32.2% | +33.6% | +28.4% | +27.1% | +15.1% | +13.5% | +17.9% | +8.4% | +23.0% | +26.8% | +25.8% |
Range$1.61B – $3.80B
CAGR+20.0%
Avg YoY Growth+19.3%
Median YoY Growth+23.0%
Current Streak3 quarters growth
R&D at Other Companies
Frequently Asked Questions
- What is Eli Lilly's r&d?
- Eli Lilly (LLY) reported r&d of $3.80B in Q4 2025.
- How has Eli Lilly's r&d changed year-over-year?
- Eli Lilly's r&d increased by 25.8% year-over-year, from $3.02B to $3.80B.
- What is the long-term trend for Eli Lilly's r&d?
- Over 4 years (2021 to 2025), Eli Lilly's r&d has grown at a 17.4% compound annual growth rate (CAGR), from $7.03B to $13.34B.
- What does r&d mean?
- Money spent on developing new products and improving existing ones.